title: Amplification of KIT, PDGFRA, VEGFR2, and EGFR in gliomas.
abstract: Receptor tyrosine kinase aberrations are implicated in the genesis of gliomas. We investigated expression and amplification of KIT, PDGFRA, VEGFR2, and EGFR in 87 gliomas consisting of astrocytomas, anaplastic astrocytomas, oligodendrogliomas, or oligoastrocytomas in tumor samples collected at the time of the diagnosis and in samples of the same tumors at tumor recurrence. Gene amplifications were investigated using either chromogenic in situ hybridization or fluorescence in situ hybridization, and protein expression using immunohistochemistry. In samples collected at glioma diagnosis, KIT and PDGFRA amplifications were more frequent in anaplastic astrocytomas than in astrocytomas, oligodendrogliomas, and oligoastrocytomas [28% versus 5% (P = 0.012) and 33% versus 2% (P = 0.0008), respectively]. VEGFR2 amplifications occurred in 6% to 17% of the gliomas at diagnosis, and EGFR amplifications in 0% to 12%. Amplified KIT was more frequently present in recurrent gliomas than in newly diagnosed gliomas (P = 0.0066). KIT amplification was associated with KIT protein expression and with presence of PDGFRA and EGFR amplifications both at the time of the first glioma diagnosis and at tumor recurrence, and with VEGFR2 amplification at tumor recurrence. Three (4%) primary gliomas and 10 (14%) recurrent gliomas that were evaluable for coamplification of KIT, PDGFRA, and VEGFR2 showed amplification of at least two of these genes; the amplicon contained amplified KIT in all 13 cases. In conclusion, besides glioblastoma, amplified KIT, PDGFRA, and VEGFR may also occur in lower-grade gliomas and in their recurrent tumors. It is currently not known whether specific tyrosine kinase inhibitors are effective in the treatment of such gliomas.
authors.affiliation: Laboratory of Molecular Oncology, Biomedicum Helsinki, Helsinki, Finland. Marjut.Puputti@hus.fi
authors.forename: Marjut
authors.initials: M
authors.lastname: Puputti
authors.forename: Olli
authors.initials: O
authors.lastname: Tynninen
authors.forename: Harri
authors.initials: H
authors.lastname: Sihto
authors.forename: Tea
authors.initials: T
authors.lastname: Blom
authors.forename: Hanna
authors.initials: H
authors.lastname: Mäenpää
authors.forename: Jorma
authors.initials: J
authors.lastname: Isola
authors.forename: Anders
authors.initials: A
authors.lastname: Paetau
authors.forename: Heikki
authors.initials: H
authors.lastname: Joensuu
authors.forename: Nina N
authors.initials: NN
authors.lastname: Nupponen
mesh_terms: D001932:Brain Neoplasms / Q000235:genetics* / Q000378:metabolism; D066246:ErbB Receptors / Q000235:genetics* / Q000378:metabolism; D005784:Gene Amplification / Q000502:physiology*; D015870:Gene Expression; D005910:Glioma / Q000235:genetics*; D006801:Humans; D019009:Proto-Oncogene Proteins c-kit / Q000235:genetics* / Q000378:metabolism; D020796:Receptor, Platelet-Derived Growth Factor alpha / Q000235:genetics* / Q000378:metabolism; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000235:genetics* / Q000378:metabolism
chemical_list: D066246:ErbB Receptors; D019009:Proto-Oncogene Proteins c-kit; D020796:Receptor, Platelet-Derived Growth Factor alpha; D040301:Vascular Endothelial Growth Factor Receptor-2